BioStock: Extensive positive media coverage for Elicera in Q3
Elicera delivers a solid third quarter supported by encouraging CARMA data in B-cell lymphoma, including a sustained complete metabolic response in the first treated patient – results that have sparked significant national media coverage. As recruitment moves into the highest dose cohort and new data are expected in spring 2026, the company is also preparing for final AdVince reporting with ELC-100.
Read the full article at biostock.se:
Extensive positive media coverage for Elicera during Q3
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/